UNSPSC 51123202: Butobendine

This classification denotes an antiarrhythmic agent with the molecular formula C32H48N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) RP2J52327K, chemically known as ( )-(s,s)-ethylenebis-((methylimino)(2-ethylethylene))bis(3,4,5-trimethoxy-benzoate). but more generally known as butobendine, which bears US NIH Compound Identifier 3037620. Butobendine most often comes in base, dihydrochloride, and hydrochloride forms.

UNSPSC 51123202 Butobendine, a Commodity code, encompasses emergency and critical-care medications supplied to state and local public safety and healthcare agencies. State and local governments procure under this code specific pharmaceutical line items for emergency medical services, fire departments, and health agencies—in practice, sealed competitive bids for Advanced Life Support medications, cooperative purchasing agreements for generic pharmaceuticals distributed through authorized wholesalers, and exploratory requests for information on direct-to-manufacturer prescription programs. Issuing bodies include city purchasing departments (notably the City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state, local, and regional members including Oregon). The work ranges from small, time-sensitive procurements for specific medication line items with firm pricing and delivery windows to larger cooperative framework agreements establishing NDC-specific pricing and supply chains with multiple authorized wholesalers.

Geographic activity centers on Florida and Minnesota, with Texas HHS and multistate cooperative reach. Representative recent opportunities include the City of Tampa Fire Rescue's sealed bid (IFB No. 26P00188, response due April 8, 2026) for four Advanced Life Support medication line items—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—with an estimated contract value of $40,000 and a one-year term plus renewal options; the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), effective July 1, 2026, with a two-year initial term; and the Texas Health and Human Services Commission's Request for Information (HHS0017013, posted March 27, 2026, due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels. The Tampa bid carries a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount for SLBE participation, and all suppliers must meet FDA compliance, cGMP certification, DSCSA compliance, and OSHA Safety Data Sheet standards.